

NOVINKY Z LETOŠNÍHO NEJVÝZNAMNĚJŠÍHO SETKÁNÍ ONKOLOGŮ

Shrnutí ze sekce precizní imunoterapie




Luboš Petruželka

Onkologická klinika 1. LF UK, VFN v Praze a UVN-VFN Praha
Ústav radiační onkologie Nemocnice Na Bulovce, Praha
Institut postgraduálního vzdělávání ve zdravotnictví, Praha

26. 6. 2020

Definitivní ukončení stagnace léčby solidních nádorů?

Kontinuální inovace léčebného armamentária – precizní imunoterapie??



Chirurgie

Radioterapie




Chemoterapie




Systémová léčba

Cílená (terčová) léčba



Imunoterapie
(check point inhibitory)




Personalizovaná
onkologie

Precizní onkologie

Biomarkery pro imunoterapii

Fenotyp/genomické markery



Klíčové klinické studie napříč solidními nádory

- Terčová léčba
- **Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA *EGFR* mutation positive (*EGFR*m) NSCLC after complete tumour resection: ADAURA (Abstract LBA5)**

Karcinomy GIT

- **KEYNOTE-177**
- Pembrolizumab as a front-line therapy in patients with microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal carcinoma
- PFS was improved by 8.3 months when [pembrolizumab](#) versus chemotherapy was used in the front-line setting.
- *The DESTINY-CRC01 trial [trastuzumab](#) deruxtecan, an antibody-drug conjugate, in refractory HER2-expressing mCRC patients. The trial demonstrated an impressive response rate, which will require further studies.*

Imunoterapie NSCLC

- **Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs. 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC):
CheckMate 9LA (Abstract 9501)**
- In the Phase III CheckMate 9LA trial, the company [presented first results](#) showing a statistically significant and clinically meaningful survival benefit with Opdivo plus Yervoy, given concomitantly with two cycles of chemotherapy for 1L metastatic NSCLC. The trial met both its primary and key secondary endpoints, showing superior OS, progression-free survival (PFS) and overall response rate (ORR) for the dual immunotherapy plus chemotherapy compared to chemotherapy alone.

Imunoterapie NSCLC

- **Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as 1L tx in patients with PD-L1-selected NSCLC (CITYSCAPE; Abstract 9503)**
- Phase II CITYSCAPE clinical trial in PD-L1-positive metastatic non-small cell lung cancer (NSCLC). The study evaluated a new checkpoint inhibitor tiragolumab and its checkpoint inhibitor atezolizumab compared to atezialone.
- Tiragolumab is a novel immunotherapy that binds to TIGIT, an immune checkpoint protein found on immune cells. Tecentriq is a PD-L1 checkpoint inhibitor. Both TIGIT and PD-L1 are involved in immune suppression. Blocking both pathways has the potential for improving anti-tumour activity.

Uroteliální karcinomy

- **Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based 1L chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis (Abstract LBA1)**
- *When combined with best supportive care, avelumab tx resulted in a median overall survival of 21.4 months compared with 14.3 months for best supportive care alone.*

Renální karcinom

- **Phase II trial of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma**

Imunoterapie u incidenčně vzácných onemocnění

- Avelumab v léčbě gestační trofoblastické nemoci
- *The majority of trophoblastic tumours relapse within 6 months, if not within the 12 months after treatment discontinuation. In this study, 8 of 15 patients (53 %) with GTT that was resistant to single-agent chemotherapy methotrexate or antibiotic actinomycin-D had no sign of disease relapse at 29 months follow-up. If disease had not relapsed after 12 months and monitoring of human chorionic gonadotropin (hCG) had concluded, researchers consider the patient cured. The hormone hCG is used as biomarker for GTT.*

Jak dál

- Bispecifické protilátky
 - *DART molecule that binds PD-1 and LAG-3*
- Modulace NK bb
 - *The APOLLO study, which looked at adaptive memory natural killer (NK) cells in recurrent [ovarian cancer](#)*
- Imunokonjugáty
- Personalizované vakcíny